Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Q3 FY22 Earnings Presentation
17 slides from Zydus Lifesciences's earnings presentation, Feb 3, 2022
Slide 1: Cover letter to stock exchanges
_________________________________________________________________________ February 3, 2022 Listing Department Code: 532321 BOMBAY STOCK EXCHANGE LIMITED P J Towers, Dalal Street, Fort, Mumbai–400 001 Listing Department Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Ku
Slide 2: Cadila Healthcare Limited Results Presentation Q3 FY22
Cadila Healthcare Limited Results Presentation Q3 FY22 3rd February, 2022
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Consolidated Financial Highlights Q3 FY22
Consolidated Financial Highlights Q3 FY22 Revenue Consolidated Revenue from operations at INR 3,655 Crores, up 1% Y-o-Y and down 3% Q-o-Q. INR Crores Y-o-Y Q-o-Q Consolidated EBIDTA at INR 753 Crores down 2% Y-o-Y and down 13% Q-o-Q. 3,655 1% -3% EBIDTA margin for Q3’22 is 20.6%, against 22.7% i
Slide 5: Consolidated Financial Performance Q3 FY22
Consolidated Financial Performance Q3 FY22 Particulars Q-o-Q Y-o-Y Q3 FY22 Q2 FY22 Q3 FY21 YTD FY22 YTD FY21 Growth INR Crores Growth Growth Revenue from operations 3,655 3,785 -3% 3,633 1% 11,465 10,807 6% 1. Reduction in GC margins is Gross Contribution 2,308 2,403 -4% 2,432 -5% 7,361 7,182 2% mai
Slide 6: Business wise Sales Q3 FY22
Business wise Sales Q3 FY22 INR Crores Ex. COVID opp. & others* (Y-o-Y (Q-o-Q ▲12%) ▼6%) Ex. COVID opp. & others* (Y-o-Y (Q-o-Q ▲17%) ▼8%) Market, Sales Value Q3 21-22 % share in consolidated sales Ex. COVID opp ▲% Growth (Y-o-Y (Q-o-Q ▲7%) ▲3%) * Others include generics business and divested brands
Slide 7: Business wise Sales YTD FY22
Business wise Sales YTD FY22 INR Crores Ex. COVID opp. & others* ▲17% Ex. COVID opp. & others* ▲22% Market, Sales Value YTD 21-22 % share in consolidated sales ▲% Growth Ex. COVID opp. ▲12% * Others include generics business and divested brands in human formulation business in India
Slide 8: India Geography: Human health formulations business
India Geography: Human health formulations business INR Crores Highlights Gained market share in our core therapies of anti-diabetic, cardiovascular, gynecology and anti-infective therapeutic area on a y-o-y basis. Lipaglyn catapulted among the top 100 brands and was ranked 92nd* in Indian pharm
Slide 9: India Geography: Consumer Wellness
India Geography: Consumer Wellness INR Crores Highlights 5 out of 7 brands maintained their leadership position in their respective categories. The business experienced lower growth in sales due to: High base during previous year comparable period Y-o-Y ▲2% which was accentuated by slowdown in
Slide 10: US Formulations Business
US Formulations Business INR Crores Highlights On a q-o-q basis the business remained flat despite continued pricing pressure in the market and decline in sales of Mesalamine products as it managed to gain volumes in other existing and new products. Launched 3 new products including “Nelarabine
Slide 11: Emerging Markets
Emerging Markets INR Crores Highlights Due to its presence in diverse geographies, the business managed to overcome challenges emerging out of political and economic uncertainty in some of the markets as these were offset by strong growth in other markets. New products dossiers filing in Q3’22:
Slide 12: ZyCov-D Vaccine Update
ZyCov-D Vaccine Update Received an order from the Government of India to supply 1 crore doses of the vaccine. Already started the supplies of the vaccine to the Government of India against their order. Supply of commercial batches of drug substance of the vaccine from the facility of Shilpa Medicare
Slide 13: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • Initiated a global pivotal Phase II(b)/III CT viz. EPICS-IIITM to evaluate its efficacy and safety in patients with PBC for the US market. • Phase II(a) results of EPICS CTs published in the journal of Hepatology demonstrated that molecule holds im
Slide 14: Updates on Innovation
Updates on Innovation NCE: ZYIL1 • Received regulatory permission to initiate Phase II(a) CTs in patients with CAPS in Australia. Biosimilars and novel biologics • Completed Phase III CTs for one mAb and received the permission from DCGI to initiate Phase III CTs for one mAb. • Submitted an applicat
Slide 15: Thank you
Thank you Zydus Corporate Park, SG Highway, Near Vaishnodevi Circle, Ahmedabad, 382481, India
Slide 16: Glossary
Glossary • Revenue from operations represents Sales and other operating revenues. • Net debt: It is defined as the sum of long-term borrowings, short-term borrowings, minus cash and cash equivalents, current investments, and other bank balances. • EBIDTA: Earnings before interest, depreciation, taxa
Slide 17: Details of other operating income, other income and foreign exchange fluctuations
Details of other operating income, other income and foreign exchange fluctuations Other Operating Income Particulars Y-o-Y Y-o-Y Q3 FY22 Q3 FY21 YTD FY22 YTD FY21 INR Crores Growth Growth Export Incentive 17 10 68.3% 37 107 -65.1% Exchange Rate Fluctuations 18 0 97 0 Processing Income 10 6 81.8% 23